-

VENU Investigation: Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Venu Holding Corporation (“Venu” or the “Company”) (NYSE:VENU) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On November 27, 2024, Venu conducted its initial public offering of 1.2 million shares priced at $10.00 per share. Then, on November 14, 2025, Venu issued a press release reporting its financial results for the third quarter of 2025. Among other items, Venu reported revenue of $5.38 million, representing a 1.3% year-over-year decline and missing consensus estimates by $2.05 million. On this news, the price of Venu shares declined by $2.37 per share, or approximately 21.45%, from $11.05 per share on November 14, 2025 to close at $8.68 on November 17, 2025.

What Should I Do?

If you purchased or otherwise acquired Venu securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

Kirby McInerney LLP

NYSE:VENU

Release Versions

Contacts

Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
investigations@kmllp.com

More News From Kirby McInerney LLP

LCID INVESTOR REMINDER: Lucid Group, Inc. Investors Have Until July 28, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until July 28, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. Th...

INVESTOR ALERT: Securities Class Action Filed Against Erasca, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) securities during the period of January 14, 2025 through April 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Erasca investments, you have until August 10, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...

INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (“the Class Period”).If you suffered a loss on your ADMA investments, you have until August 10, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after...
Back to Newsroom